Rosetta Genomics to Announce First Quarter 2007 Financial Results and Host Conference Call on Tuesday, May 8, 2007

REHOVOT, Israel and NEW BRUNSWICK, New Jersey, May 1

May 01, 2007, 01:00 ET from Rosetta Genomics Ltd

/PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (Nasdaq:   ROSG) announced
 that the company will report first quarter 2007 financial results on
 Tuesday, May 8, 2007, after U.S. financial markets close. Following the
 announcement, senior management will host a conference call and webcast at
 4:30 p.m. Eastern Time to discuss financial results and corporate
     Conference Call Details
     To access the live conference on May 8 at 4:30 p.m. Eastern Time via
 phone, please dial (866)-409-1557 from the United States and Canada or
 +1-913-312-1237 internationally. The conference passcode is 3026948. Please
 dial in approximately fifteen minutes prior to the start of the call.
     A telephone replay will be available beginning approximately one hour
 after the call through May 15 and may be accessed by dialing (888)-203-1112
 from the United States and Canada or +1-719-457-0820 internationally. The
 replay passcode is 3026948.
     To access the live and subsequently archived webcast of the conference
 call, go to the Investor Relations section of the Company's website at Please connect to the web site at least 15 minutes
 prior to the call to allow for any software download that may be necessary.
     About Rosetta Genomics
     Rosetta Genomics (Nasdaq:   ROSG) is a leader in the development of
 microRNA-based diagnostics and therapeutics. The company's integrative
 research platform combining bioinformatics and state-of-the-art laboratory
 processes has led to the discovery of hundreds of biologically validated
 novel human microRNAs. Building on its strong IP position and strategic
 alliances with leading biotechnology companies, Rosetta Genomics is working
 to develop a full range of diagnostic and therapeutic products based on
 microRNAs. The company's primary focus is in the development of
 microRNA-based products to diagnose and treat different forms of cancer and
 infectious diseases.
     Media & Investors
     Ron Kamienchick
     T: +972-8-948-4785

SOURCE Rosetta Genomics Ltd